---
schema_version: "secwatch.filing_event.v1"
accession: "0001654954-26-005989"
form_type: "8-K"
ticker: "PBSV"
cik: "0001304161"
company_name: "Pharma-Bio Serv, Inc."
filed_at: "2026-06-15T21:06:05+00:00"
generated_at: "2026-06-15T21:08:08.193685+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.4
calibrated_materiality_score: 0.4
confidence: "high"
source: SEC EDGAR
---

# Pharma-Bio Serv Q1 revenue $2.7M, net income $0.2M; both up YoY

## Summary
- Three-month revenue $2.7M, up $0.3M vs prior year; net income $0.2M, up $0.1M.
- Six-month revenue $5.0M, up $0.1M; net income $0.3M, up $0.2M.
- CEO cites strategic focus on high-return markets and cost management for profit improvement.

## SEC filing metadata
- accession: 0001654954-26-005989
- form_type: 8-K
- ticker: PBSV
- cik: 0001304161
- company_name: Pharma-Bio Serv, Inc.
- filed_at: 2026-06-15T21:06:05+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.4
- calibrated_materiality_score: 0.4
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1304161/000165495426005989/0001654954-26-005989-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1304161/000165495426005989/pbsv_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001654954-26-005989
- JSON: https://secwatch.observer/filing/0001654954-26-005989.json
- Plain text: https://secwatch.observer/filing/0001654954-26-005989.txt

## Key facts
- Earnings Releases
  Pharma-Bio Serv, Inc. reported the quarter ended April 30, 2026 results: revenue approximately $2.7 million, net income approximately $0.2 million.
  - Period: the quarter ended April 30, 2026
  - Revenue: approximately $2.7 million
  - Net income: approximately $0.2 million
  - Result: reported results
  source text: revenues for the three and six months ended April 30, 2026 were approximately $2.7 million and $5.0 million, respectively, representing increases of approximately $0.3 million and $0.1 million compared to the same periods last year. Net income for the three and six months ended April 30, 2026 was approximately $0.2 million and $0.3 million, respectively, representing increases of approximately $0.1 million and $0.2 million compared to the same periods last year.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1304161/000165495426005989/0001654954-26-005989-index.htm
- Earnings Releases
  Pharma-Bio Serv, Inc. reported the six months ended April 30, 2026 results: revenue approximately $5.0 million, net income approximately $0.3 million.
  - Period: the six months ended April 30, 2026
  - Revenue: approximately $5.0 million
  - Net income: approximately $0.3 million
  - Result: reported results
  source text: revenues for the three and six months ended April 30, 2026 were approximately $2.7 million and $5.0 million, respectively, representing increases of approximately $0.3 million and $0.1 million compared to the same periods last year. Net income for the three and six months ended April 30, 2026 was approximately $0.2 million and $0.3 million, respectively, representing increases of approximately $0.1 million and $0.2 million compared to the same periods last year.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1304161/000165495426005989/0001654954-26-005989-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.